RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Protagonist Therapeutics Stock

Protagonist Therapeutics Revenue 2024

Protagonist Therapeutics Revenue

300.2 M USD

Ticker

PTGX

ISIN

US74366E1029

WKN

A2AP32

In 2024, Protagonist Therapeutics's sales reached 300.2 M USD, a 400.33% difference from the 60 M USD sales recorded in the previous year.

The Protagonist Therapeutics Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e536.14-
2028e365.57-
2027e191.41-
2026e180.47-
2025e187.1-
2024e300.2-
202360-
202226.58-
202127.36-
202028.63-
20190.23-
201830.93-
201720.06-
2016--
2015--
2014--

Protagonist Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Protagonist Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Protagonist Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Protagonist Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Protagonist Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Protagonist Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Protagonist Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Protagonist Therapeutics’s growth potential.

Protagonist Therapeutics Revenue, EBIT and net profit per share

DateProtagonist Therapeutics RevenueProtagonist Therapeutics EBITProtagonist Therapeutics Net Income
2029e536.14 M undefined0 undefined201.26 M undefined
2028e365.57 M undefined169.54 M undefined59.18 M undefined
2027e191.41 M undefined9.41 M undefined-46.56 M undefined
2026e180.47 M undefined-69.38 M undefined-135.12 M undefined
2025e187.1 M undefined12.82 M undefined-99.98 M undefined
2024e300.2 M undefined99.48 M undefined107.22 M undefined
202360 M undefined-93.65 M undefined-78.96 M undefined
202226.58 M undefined-131.37 M undefined-127.39 M undefined
202127.36 M undefined-125.85 M undefined-125.55 M undefined
202028.63 M undefined-64.51 M undefined-66.15 M undefined
2019230,000 undefined-80.52 M undefined-77.19 M undefined
201830.93 M undefined-42.27 M undefined-38.92 M undefined
201720.06 M undefined-37.9 M undefined-36.96 M undefined
20160 undefined-32.67 M undefined-37.74 M undefined
20150 undefined-14.79 M undefined-14.93 M undefined
20140 undefined-9.32 M undefined-11.22 M undefined

Protagonist Therapeutics stock margins

The Protagonist Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Protagonist Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Protagonist Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Protagonist Therapeutics's sales revenue. A higher gross margin percentage indicates that the Protagonist Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Protagonist Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Protagonist Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Protagonist Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Protagonist Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Protagonist Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Protagonist Therapeutics Margin History

Protagonist Therapeutics Gross marginProtagonist Therapeutics Profit marginProtagonist Therapeutics EBIT marginProtagonist Therapeutics Profit margin
2029e0 %0 %37.54 %
2028e0 %46.38 %16.19 %
2027e0 %4.92 %-24.32 %
2026e0 %-38.45 %-74.87 %
2025e0 %6.85 %-53.44 %
2024e0 %33.14 %35.72 %
20230 %-156.09 %-131.59 %
20220 %-494.24 %-479.27 %
20210 %-459.98 %-458.88 %
20200 %-225.32 %-231.05 %
20190 %-35,008.69 %-33,560.87 %
20180 %-136.66 %-125.83 %
20170 %-188.93 %-184.25 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %

Protagonist Therapeutics Aktienanalyse

What does Protagonist Therapeutics do?

Protagonist Therapeutics Inc is a biopharmaceutical company focused on the development and commercialization of novel peptide therapies. The company was founded in 2002 and is headquartered in Newark, California. The history of Protagonist Therapy began with the discovery of a new type of molecules called peptides, which can be used as potential drugs for various diseases. This discovery was the result of years of research and collaboration between academics and leading pharmaceutical companies. Protagonist Therapeutics' business model is focused on developing and distributing new peptide therapies in the pharmaceutical industry. The company works closely with leading academics and biotechnology companies to advance its research and development projects. Protagonist Therapeutics is divided into several divisions focusing on different therapeutic areas. These include gastrointestinal diseases, immunology, and oncology. Each division works on developing new peptide therapies specifically tailored to their respective therapeutic areas. One example of a product from Protagonist Therapeutics is PTG-300, which was developed for the treatment of iron deficiency anemia. PTG-300 is a synthetic peptide that promotes increased iron uptake in the body to combat iron deficiency. Another product from Protagonist Therapeutics is PTG-200, which was developed for the treatment of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. PTG-200 is a peptide that blocks the action of certain enzymes that amplify inflammation in the intestine. Overall, Protagonist Therapeutics aims to establish itself as a leading provider of peptide therapies in the pharmaceutical industry. The company has a strong financial foundation, including a successful IPO in 2016, and is continuously working on developing new products to expand and grow the company. Protagonist Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Protagonist Therapeutics's Sales Figures

The sales figures of Protagonist Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Protagonist Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Protagonist Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Protagonist Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Protagonist Therapeutics stock

How much revenue did Protagonist Therapeutics generate this year?

Protagonist Therapeutics has achieved a revenue of 300.2 M USD this year.

How much was the turnover of the company Protagonist Therapeutics compared to the previous year?

The revenue of Protagonist Therapeutics has increased by 400.33% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Protagonist Therapeutics?

The revenue of Protagonist Therapeutics is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Protagonist Therapeutics measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Protagonist Therapeutics so important for investors?

The revenue of Protagonist Therapeutics is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Protagonist Therapeutics pay?

Over the past 12 months, Protagonist Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Protagonist Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Protagonist Therapeutics?

The current dividend yield of Protagonist Therapeutics is .

When does Protagonist Therapeutics pay dividends?

Protagonist Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Protagonist Therapeutics?

Protagonist Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Protagonist Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Protagonist Therapeutics located?

Protagonist Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Protagonist Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Protagonist Therapeutics from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Protagonist Therapeutics pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Protagonist Therapeutics in the year 2023?

In the year 2023, Protagonist Therapeutics distributed 0 USD as dividends.

In which currency does Protagonist Therapeutics pay out the dividend?

The dividends of Protagonist Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Protagonist Therapeutics

Our stock analysis for Protagonist Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Protagonist Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.